Clinical trial
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE)
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE
ClinicalTrials.gov ID: NCT02426125
Sponsor: Eli Lilly and Company
Information provided by: Eli Lilly and Company (Responsible Party)
Last Update Posted: 2023-08-21
Brief Summary:
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
Official Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Intervention / Treatment:
- Drug: Ramucirumab
- Drug: Docetaxel
- Drug: Placebo
| Category | Value |
|---|---|
| Study Start (Actual) | 2015-07-13 |
| Primary Completion (Actual) | 2017-04-21 |
| Study Completion (Actual) | 2022-07-26 |
| Enrollment (Actual) | 530 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
15679
I4T-MC-JVDC (Other Identifier) (OTHER: Eli Lilly and Company) 2014-003655-66 (EudraCT Number) |